Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 6
2020 5
2021 5
2022 3
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer.
Katayama Y, Yamada T, Tanimura K, Tokuda S, Morimoto K, Hirai S, Matsui Y, Nakamura R, Ishida M, Kawachi H, Yoneda K, Hosoya K, Tsuji T, Ozasa H, Yoshimura A, Iwasaku M, Kim YH, Horinaka M, Sakai T, Utsumi T, Shiotsu S, Takeda T, Katayama R, Takayama K. Katayama Y, et al. Among authors: hosoya k. NPJ Precis Oncol. 2023 Jan 26;7(1):12. doi: 10.1038/s41698-023-00350-7. NPJ Precis Oncol. 2023. PMID: 36702855 Free PMC article.
Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation-positive Lung Cancer.
Ogimoto T, Ozasa H, Tsuji T, Funazo T, Yamazoe M, Hashimoto K, Yoshida H, Hosoya K, Ajimizu H, Nomizo T, Yoshida H, Hamaji M, Menju T, Yoshizawa A, Date H, Hirai T. Ogimoto T, et al. Among authors: hosoya k. Mol Cancer Ther. 2024 Apr 2;23(4):564-576. doi: 10.1158/1535-7163.MCT-23-0371. Mol Cancer Ther. 2024. PMID: 38052760
Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer.
Yamazoe M, Ozasa H, Tsuji T, Funazo T, Yoshida H, Hashimoto K, Hosoya K, Ogimoto T, Ajimizu H, Yoshida H, Itotani R, Sakamori Y, Kuninaga K, Aoki W, Hirai T. Yamazoe M, et al. Among authors: hosoya k. Cancer Sci. 2023 Feb;114(2):546-560. doi: 10.1111/cas.15622. Epub 2022 Nov 23. Cancer Sci. 2023. PMID: 36285485 Free PMC article.
Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series.
Hashimoto K, Ozasa H, Yoshizawa A, Yoshida H, Ogimoto T, Hosoya K, Yamazoe M, Ajimizu H, Funazo T, Yoshida H, Sakamori Y, Hirai T. Hashimoto K, et al. Among authors: hosoya k. Oncol Lett. 2022 Sep 22;24(5):402. doi: 10.3892/ol.2022.13522. eCollection 2022 Nov. Oncol Lett. 2022. PMID: 36276492 Free PMC article.
Author Correction: Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.
Ajimizu H, Ozasa H, Sato S, Funazo T, Sakamori Y, Nomizo T, Kuninaga K, Ogimoto T, Hosoya K, Yamazoe M, Tsuji T, Yoshida H, Itotani R, Ueno K, Kim YH, Muro S, Hirai T. Ajimizu H, et al. Among authors: hosoya k. Sci Rep. 2023 Feb 6;13(1):2117. doi: 10.1038/s41598-023-29102-0. Sci Rep. 2023. PMID: 36747076 Free PMC article. No abstract available.
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002.
Tamiya M, Fujikawa K, Suzuki H, Yokoyama T, Uenami T, Tamiya A, Sato Y, Saito G, Uchida J, Morita M, Hirashima T, Fukuda Y, Kanazu M, Hosoya K, Suzuki T, Ueno K, Fujimoto D, Kumagai T, Teramukai S. Tamiya M, et al. Among authors: hosoya k. Invest New Drugs. 2022 Apr;40(2):361-369. doi: 10.1007/s10637-021-01203-5. Epub 2022 Jan 28. Invest New Drugs. 2022. PMID: 35088212
22 results